These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22540538)

  • 1. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds.
    Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T
    Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data.
    Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T
    Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of UDP-glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs.
    Li T; Zheng Y; Fu F; Ji H; Chen X; Zhao Y; Zhao D; Li N; Zhang L
    Xenobiotica; 2011 Jul; 41(7):530-7. PubMed ID: 21524190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
    Gill KL; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
    Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
    Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
    Nishimuta H; Sato K; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
    Kaji H; Kume T
    Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.
    Uchihashi S; Fukumoto H; Onoda M; Hayakawa H; Ikushiro S; Sakaki T
    Drug Metab Dispos; 2011 May; 39(5):803-13. PubMed ID: 21346002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
    Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
    Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.
    Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T
    Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.
    Mizuma T
    Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
    Cubitt HE; Houston JB; Galetin A
    Pharm Res; 2009 May; 26(5):1073-83. PubMed ID: 19184618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.
    Furukawa T; Naritomi Y; Tetsuka K; Nakamori F; Moriguchi H; Yamano K; Terashita S; Tabata K; Teramura T
    Xenobiotica; 2014 Mar; 44(3):205-16. PubMed ID: 23962030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7.
    Gaganis P; Miners JO; Knights KM
    Biochem Pharmacol; 2007 May; 73(10):1683-91. PubMed ID: 17343829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucuronidation of zearalenone, zeranol and four metabolites in vitro: formation of glucuronides by various microsomes and human UDP-glucuronosyltransferase isoforms.
    Pfeiffer E; Hildebrand A; Mikula H; Metzler M
    Mol Nutr Food Res; 2010 Oct; 54(10):1468-76. PubMed ID: 20397195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.
    Hanioka N; Tanaka S; Moriguchi Y; Narimatsu S
    Pharmacology; 2012; 90(3-4):117-24. PubMed ID: 22814440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.